Yasutaka Inuzuka

Yasutaka Inuzuka

Auto-generated profile, based on publicly available information

Yasutaka Inuzuka

Department of Cardiology, Shiga Medical Center for Adults, Moriyama, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
YMYuya Matsue
Yuya Matsue
NKNobuyuki Kagiyama
Nobuyuki Kagiyama
TYTetsuo Yamaguchi
Tetsuo Yamaguchi
SKShunsuke Kuroda
Shunsuke Kuroda
TOTakahiro Okumura
Takahiro Okumura
TKTakeshi Kitai
Takeshi Kitai

1 September 2019 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
NKNobuyuki Kagiyama
Nobuyuki Kagiyama
TKTakeshi Kitai
Takeshi Kitai
AHAkihiro Hayashida
Akihiro Hayashida
TYTetsuo Yamaguchi
Tetsuo Yamaguchi
TOTakahiro Okumura
Takahiro Okumura
YMYuya Matsue
Yuya Matsue

24 April 2020 in Circulation Journal
Verified
Journal Article
Open access
PDF file
YTYasuaki Takeji
Yasuaki Takeji
TTTomohiko Taniguchi
Tomohiko Taniguchi
TMTakeshi Morimoto
Takeshi Morimoto
NSNaritatsu Saito
Naritatsu Saito
KAKenji Ando
Kenji Ando
OIon behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
on behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
Background:There are no data comparing transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) outcomes in real clinical practice in Japan. Methods and Results:We combined 2 independent registries, the K-TAVI Registry (a 6-center prospective registry of consecutive patients who underwent TAVI) and the CURRENT AS Registry (a large, 27-center registry of 3,815 consecutive patients with severe aortic stenosis [AS]). In the K-TAVI Registry, 338 patients underwent TAVI with SAPIEN XT balloon-expandable valves from October 2013 to January 2016, whereas in the CURRENT AS Registry 237 patients with severe AS underwent SAVR from January 2003 to December 2011. Propensity score matching was conducted, with final cohort comprising 306 patients. The cumulative 2-year incidence of all-cause death and heart failure (HF) hospitalization did not differ significantly between the TAVI and SAVR groups (13.7% vs. 12.4% [P=0.81] and 7.9% vs 3.9% [P=0.13], respectively). After adjusting for residual confounders, there were no significant differences between the TAVI and SAVR groups in the risk for all-cause death (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.35–1.58; P=0.43) or HF hospitalization (HR 1.27; 95% CI 0.40–4.59; P=0.69). Conclusions:These findings from 2 independent Japanese registries suggest that the 2-year risk of all-cause mortality and HF does not differ significantly between TAVI and SAVR groups in real-world practice in Japan.

2 July 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YKYuichi Kawase
Yuichi Kawase
TKTakao Kato
Takao Kato
TMTakeshi Morimoto
Takeshi Morimoto
RHReo Hata
Reo Hata
RMRyosuke Murai
Ryosuke Murai
TKTakeshi Kimura
Takeshi Kimura
Background: Admission systolic blood pressure has emerged as a predictor of postdischarge outcomes of patients with acute decompensated heart failure; however, its validity in varied clinical conditions of this patient subset is unclear. The aim of this study was to further explore the prognostic value of admission systolic blood pressure in patients with acute decompensated heart failure.Methods: The Kyoto Congestive Heart Failure (KCHF) registry is a prospective, observational, multicenter cohort study enrolling consecutive patients with acute decompensated heart failure from 19 participating hospitals in Japan. Clinical characteristics at baseline and prognosis were examined by the following value range of admission systolic blood pressure: <100, 100–139, and ≥140 mmHg. The primary outcome measure was defined as all-cause death after discharge. Subgroup analyses were done for prior hospitalization for heart failure, hypertension, left ventricular ejection fraction, and medications at discharge. We excluded patients with acute coronary syndrome or insufficient data.Results: We analyzed 3564 patients discharged alive out of 3804 patients hospitalized for acute decompensated heart failure. In the entire cohort, lower admission systolic blood pressure was associated with poor outcomes (1-year cumulative incidence of all-cause death: <100 mmHg, 26.8%; 100–139 mmHg, 20.2%; and ≥140 mmHg, 15.1%, p<0.001). The magnitude of the effect of lower admission systolic blood pressure for postdischarge all-cause death was greater in patients with prior hospitalization for heart failure, heart failure with reduced left ventricular ejection fraction, and β-blocker use at discharge than in those without.Conclusions: Admission systolic blood pressure is useful for postdischarge risk stratification in patients with acute decompensated heart failure. Its magnitude of the effect as a prognostic predictor may differ across clinical conditions of patients.

5 May 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EYErika Yamamoto
Erika Yamamoto
TKTakao Kato
Takao Kato
HYHidenori Yaku
Hidenori Yaku
TMTakeshi Morimoto
Takeshi Morimoto
YIYasutaka Inuzuka
Yasutaka Inuzuka
TKTakeshi Kimura
Takeshi Kimura
Objective: The complex link between nutritional status, protein and lipid synthesis, and immunity plays an important prognostic role in patients with heart failure. However, the association between appetite loss at discharge and long-term outcome remains unclear. Methods: The Kyoto Congestive Heart Failure registry is a prospective cohort study that enrolled consecutive patients hospitalized for acute decompensated heart failure (ADHF) in Japan. We assessed 3528 patients alive at discharge, and for whom appetite and follow-up data were available. We compared one-year clinical outcomes in patients with and without appetite loss at discharge. Results: In the multivariable logistic regression analysis using 19 clinical and laboratory factors with P value < 0.1 by univariate analysis, BMI < 22 kg/m2 (odds ratio (OR): 1.57, 95% confidence interval (CI): 1.11–2.24, P = 0.01), CRP >1.0mg/dL (OR: 1.49, 95%CI: 1.04–2.14, P = 0.03), and presence of edema at discharge (OR: 4.30, 95%CI: 2.99–6.22, P<0.001) were associated with an increased risk of appetite loss at discharge, whereas ambulatory status (OR: 0.57, 95%CI: 0.39–0.83, P = 0.004) and the use of ACE-I/ARB (OR: 0.70, 95% CI: 0.50–0.98, P = 0.04) were related to a decreased risk in the presence of appetite loss. The cumulative 1-year incidence of all-cause death (primary outcome measure) was significantly higher in patients with appetite loss than in those without appetite loss (31.0% vs. 15.0%, P<0.001). The excess adjusted risk of appetite loss relative to no appetite loss remained significant for all-cause death (hazard ratio (HR): 1.63, 95%CI: 1.29–2.07, P<0.001). Conclusions: Loss of appetite at discharge was associated with worse 1-year mortality in patients with ADHF. Appetite is a simple, reliable, and useful subjective marker for risk stratification of patients with ADHF.

1 March 2021 in Journal of Cardiology
Verified
Journal Article
Closed access
RHReo Hata
Reo Hata
TKTakao Kato
Takao Kato
HYHidenori Yaku
Hidenori Yaku
TMTakeshi Morimoto
Takeshi Morimoto
YKYuichi Kawase
Yuichi Kawase
TKTakeshi Kimura
Takeshi Kimura